UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

~~PURSUANT~~For TOthe ~~RULE~~month ~~13a-16~~of ORAugust ~~15d-16~~2025

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-41661

~~Jin~~JIN ~~Medical~~MEDICAL ~~International~~INTERNATIONAL ~~Ltd~~LTD.

(Exact name of registrant as specified in its charter)

No. 33 Lingxiang Road, Wujin District

Changzhou City, Jiangsu Province

People’s Republic of China

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Jin Medical Launches Production at Plant No. 3 of Its Chuzhou Manufacturing Facility

Jin Medical International Ltd. (Nasdaq: ZJYL) (“Jin Medical”, and together with all its subsidiaries, the “Company”), a Nasdaq-listed provider of rehabilitation medical equipment reports that its wholly owned subsidiary, ZhongJin Medical Equipment (Anhui) Co., Ltd. (“Zhongjin Anhui”), has officially launched production at Plant No. 3 of Zhongjin Anhui’s intelligent manufacturing facility in Chuzhou, Anhui, China (the “Facility”). The Company reports that the Facility is designed with an annual production capacity of approximately 200,000 units, laying a strong foundation for the Company’s steady expansion across regional frontiers.

On July 16, 2025 (China time), the Company published a press release a copy of which is attached herein as Exhibit 99.1.

INCORPORATION BY REFERENCE

~~The~~This ~~above text of this~~ report ~~under~~on ~~the~~Form ~~section title~~6-K (“~~Jin~~Report”) shall ~~Medical~~be ~~Launches~~deemed ~~Production~~to ~~at Plant No. 3 of Its Chuzhou Manufacturing Facility” shall~~ be incorporated by reference into the ~~Company’s~~ registration statement on ~~Form~~ F-3 (File No. 333-288314) of Jin Medical International Ltd., ~~initially~~a Cayman Islands exempted company (the “Company”) filed with the ~~SEC~~U.S. onSecurities and Exchange Commission June 25, 2025 ~~as subsequently amended~~), ~~and~~(“Registration beStatement”), aand ~~part~~into ~~thereof~~each ~~from~~prospectus ~~the~~or ~~date~~prospectus onsupplement ~~which~~outstanding ~~this~~under ~~Report is furnished to~~ the ~~SEC,~~Registration Statement, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

EXPLANATORY NOTE

The Company is furnishing this current report on Form 6-K to provide its unaudited condensed consolidated financial statements for the six months ended March 31, 2025, attached as Exhibit 99.1 to this report of foreign private issuer on Form 6-K,. and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended March 31, 2025 is attached as Exhibit 99.2 to this report of foreign private issuer on Form 6-K

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Form 6-K Report and the exhibits hereto contain certain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions.

Many of these statements are based on our assumptions about factors that are beyond our ability to control or predict and are subject to significant risks and uncertainties that are described more fully in “Item 3. Key Information-D. Risk Factors” on our annual report on Form 20-F filed with the SEC on January 24, 2025. Any of these factors or a combination of these factors could materially affect our future results of operations and the ultimate accuracy of the forward-looking statements. Fluctuations in our future financial results may negatively impact the value of our Class A ordinary shares. In addition to these important factors, important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, among other things:

●

assumptions about our future financial and operating results, including revenue, income, expenditures, cash balances, and other financial items;

●

our ability to execute our growth, and expansion, including our ability to meet our goals;

●

current and future economic and political conditions;

●

our capital requirements and our ability to raise any additional financing which we may require;

●

our ability to attract clients and further enhance our brand recognition;

●

our ability to hire and retain qualified management personnel and key employees in order to enable us to develop our business;

●

trends and competition in the education industry;

●

other assumptions described in this Report underlying or relating to any forward-looking statements.

~~EXHIBIT~~Should ~~INDEX~~one or more of the foregoing risks or uncertainties materialize, should any of our assumptions prove incorrect, or should we be unable to address any of the foregoing factors, our actual results may vary in material and adverse respects from those projected in these forward-looking statements. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects, on us. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements.

Exhibit No.		Description
99.1		Press Release dated July 16, 2025

The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s annual report and other filings with the U.S. Securities and Exchange Commission. As a result, you are cautioned not to rely on any forward-looking statements.

Financial Statements and Exhibits.

Exhibits:

Exhibit No.		Description
99.1		Unaudited Condensed Consolidated Financial Statements as of March 31, 2024 and for the Six Months Ended March 31, 2025 and 2024.
99.2		Operating and Financial Review and Prospects in Connection with the Unaudited Condensed Consolidated Financial Statements for the Six Months March 31, 2025 and 2024.
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, ~~thereunto~~ thereunto duly authorized.

	Jin Medical International Ltd.
Date: July 16, 2025	By:	/s/ Erqi Wang
Date: August 20, 2025	By:	/s/ Erqi Wang
		Erqi Wang
		Chief Executive Officer

	By:	/s/ Ziqiang Wang
		Ziqiang Wang
		Chief Financial Officer

Filing Compare · Jin Medical International Ltd.